Dr. Jingsong Wang, is our Principal Founder, Chairman and Chief Executive Officer. Prior to founding our company, Dr. Wang served as Head of China R&D and Head of Translational Medicine, Asia Pacific, at Sanofi. He is a former attending physician and clinical fellow at Harvard Medical School. Dr. Wang received his Ph.D. in Molecular Pharmacology from China Pharmaceutical University and completed a Molecular Immunology Research Fellowship at Dr. Laurie Glimcher's laboratory at the Harvard School of Public Health.

Dr. Yiping Rong is CSO of Harbour BioMed. He is a well-recognized scientist with about 20 years' experience of biomedical research and drug discovery. Prior to joining Harbour BioMed in 2016, he worked in Sanofi, JNJ and Roche and built strong expertise in cancer biology and pharmacology. He led and contributed to >15 programs entering clinical trials. He is also involved in translational research work for a few drugs. Multiple mAb or bispecific antibodies generated from his team were out licensed to MNCs. Some highly innovative first-in-class projects are in clinical trials. He worked on apoptosis, epigenetics, immuno-oncology, and cancer cell signaling fields and led the drug discovery projects including kinase, enzyme, receptor/ligand, protein-protein-interaction targets by small molecules or monoclonal antibodies. Dr. Rong received his Ph.D. degree in Pharmacology from Case Western Reserve University (Cleveland, Ohio). He is the member of American Association of Cancer Research and has more than twenty publications in cancer research field, including Nature Genetics, Molecular Cell, PNAS papers. He is also the inventor of dozens of patents in drug discovery field.

Dr. Xiaolu Tao is currently President of Harbour Therapeutics. She has more than ten years of experience in drug R&D in the United States, and has been responsible for the translational medicine and clinical pharmacology of developing chemical drugs, biological drugs and biosimilars in internationally renowned pharmaceutical companies such as Bristol Myers Squibb (BMS) and Novartis. The projects that she was responsible for or supported include: Belatacept (Nulojix^®), which has been approved in the United States, Europe, and many other regions of the world; new formulation of biosimilar Binocrit^® approved in Europe; as well as the global development of clinical stage anti-IP10 humanized antibody Eldelumab; Daclatasvir-TRIO for hepatitis C; and biosimilars of bevacizumab and aflibercept.

Dr. Tao returned to China in 2016, and then worked as Head of Clinical Pharmacology in Simcere Pharmaceutical and CStone Pharmaceuticals, building and managing the clinical pharmacology team. During this period, she was responsible for the bridging study and successful approval in China of Abatecept (Orencia^®) and supported several global clinical trials of multiple molecules. Under her supporting, sugemalimab (anti-PD-L) successfully received the ODD and BTD designations from the FDA; Pralsetinib and Avapritinib successfully submitted the NDAs in China; and Ivosidenib successfully submitted the NDA in Taiwan, China. After joining Harbour BioMed, Dr. Tao served as Vice President of Translational Development and Early Clinical Development as well as Chief Product Development Officer, with overall responsibility for the company's clinical pipelines. In the past few years, several FIC products have received IND approvals and entered clinical development in the United States and China.

Dr. Ben Chih is Chief Scientific Officer of Neurosciences, Harbour BioMed US. He is a seasoned neuroscientist with 18 years of industry experience in drug discovery for neuroscience, including 13 years at the renowned Genentech. Ben holds a bachelor's degree in molecular biology from Carnegie Mellon University and a PhD in Physiology from Columbia University. Before joining Harbour BioMed US, Dr. Chih served as Entrepreneur-In-Residence at 82VS Venture Studio and Alloy Therapeutics Inc. He co-founded Restoration Biosciences and Aldebaran Therapeutics, where he spearheaded the development of innovative therapies targeting neuroinflammation and ocular diseases. Prior to his entrepreneurial ventures, Dr. Chih held the position of project team leader at prominent biotech companies like Elan and Genentech.

Dr. Chih's expertise spans neurodegeneration, brain shuttle antibody technologies, oligonucleotide drug discovery, and human iPSC disease modeling. His contributions to the field have been recognized with the prestigious Genentech Innovation Award. He is a co-inventor on 7 patents and has authored 16 publications in top-tier journals, including Science, Neuron, Nature Cell Biology, and Nature Communications.

In his role as Chief Scientific Officer of Neurosciences, Dr. Chih will be responsible for incubating the NewCo and translating the concept into practice. He will develop and execute the company's scientific vision and strategy, aligning it with the company's business goals. Additionally, Dr. Chih will build and nurture scientific innovation and the US business ecosystem to support the company's growth needs. With his wealth of experience, expertise, and proven track record, Dr. Ben Chih is poised to lead the company's neuroscience initiatives, driving innovation, and advancing the frontiers of drug discovery in this critical field.

Dr. Michael Lee is Senior Vice President, Head of Biometrics. Dr. Lee holds a PhD degree in Biostatistics from the University of California, Los Angeles, and a BS degree in Applied Mathematics from Peking University, Beijing, China. Prior to his returning to China and joining Harbour BioMed in 2019, his pharmaceutical experience included 10 and 14 years of drug development at the Merck & Co (MSD) and Johnson & Johnson global R&D sites in New Jersey, USA, respectively. During the 20+ years of his tenure in USA, he supported 20+ compound development in various roles, significantly contributed to the successful approvals of highly visible products, such as blockbuster Xarelto^® and first FDA-approved TB drug in 40 years Sirturo^®. In addition to his rich industry experience, he had given numerous short courses and invited presentation, and been an adjunct profession for 4 years, teaching graduate level courses, at the School of Public Health, Rutgers University, New Jersey, USA.

Dr. Lee is the biostatistics Subject Matter Expert (SME) in Harbour BioMed. In addition to managing the Biometrics group, he participates company's product development strategy discussion, and he also plays a product development leader role.

Dr. Yuanqing Wei is Vice President and Head of Translational Development. She holds a PhD from Jiangnan University. Before joining Harbour BioMed, she worked in CStone Pharmaceuticals as Bioanalysis Director, Covance Pharmaceutical R&D (Shanghai) Co., Ltd. (Now LabCorp) as Senior Manager/Responsible Scientist of large molecule bioanalysis group, and WuXi AppTec bioanalysis team, over 18+ years bioanalysis experience, supporting bioanalysis from pre-clinical and clinical studies to meet the NMPA/FDA/OECD regulatory requirement.

Mr. Youchen (YC) Chen is Vice President and Head of Investor Relations & Corporate Development. YC holds a Bachelor in law from Fudan University and an MBA from McDonough School of Business, Georgetown University. Before joining Harbour BioMed, he was CFO at a clinical-stage radiopharmaceutical startup and also worked as Senior Vice President in the China Investment Banking team at Credit Suisse, advising Greater China healthcare and tech companies on strategic and financing transactions. Prior to rejoining Credit Suisse, he worked as Head of Corporate Finance at Yidu Tech (2158. HK) and as Audit Assistant Manager at KPMG.

At Harbour BioMed, YC is responsible for developing and executing corporate strategy for corporate investment opportunities, maintaining and building up good relationships with existing and potential investors and filling the need to strengthen our investor relations capabilities, with a special focus on the Hong Kong market and China region.

Amy Jiang has almost 30 years of experience in the medical and pharmaceutical industry, including 5-year of clinical practice, 10-year of clinical trial monitoring and operational management, and more than 10-year of GxP quality system management and operations.

Joined Harbour BioMed in Nov. 2019, and currently is Vice President and Chief of Staff, responsible for GxP Quality Management, and Administration, Supply Chain, and ITS, deepening the landing and development of the company's culture, promoting the operational efficiency, and comprehensively improving the company's management level and teamwork ability. Before that, Amy served in Sanofi China R&D, was responsible for coordinating local operations and global activities and interacting internally and externally as China R&D Site Head, GxP quality management system and operations as China R&D Quality Head, and ten years in clinical research and operations, successfully led several large-scale clinical trials in different therapeutic areas such as oncology and cardiovascular.

Prior to joining the pharmaceutical industry, Amy graduated from the Medical School of Shanghai Jiaotong University (formerly Shanghai Second Medical University), majoring in clinical medicine; and has worked as an oncologist in a Shanghai Tier-3 hospital for 5 years.

In the industry, Amy is keen to promote the development of clinical trials in China. She is working as an advisory board member in China Quality Assurance Forum (CQAF) and served as a course professor at the IED of NMPA and Yeehong Business School.

Dr. Bruce Zhang is Vice President and Head of Legal Affairs. Bruce is responsible for the management and improvement of the legal and IP system, and supporting the Company's major projects.

Bruce holds his Master and PhD degrees from Fudan University and Bachelor degree from Nanjing University, and he has more than 20 years' experiences from both international law firms and inhouse roles of multi-national companies.

Prior to joining the Company, Bruce was Legal Head for Greater China of DaVita, responsible for financing and investment, general corporate governance and compliance.